Table 6 Survival analysis results.

From: Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer

Follow-up period

Control group survivors (%)

Experimental group survivors (%)

Chi-squared

P-value

Significance

1-year

34 (82.93%)

40 (97.56%)

3.463

0.063

No

2-year

20 (48.78%)

29 (70.73%)

3.246

0.072

No

3-year

7 (17.07%)

16 (39.02%)

3.867

0.049

Yes

Back to article page